PharmaJet announced that its Tropis system is now the exclusive intradermal delivery system for two novel COVID-19 vaccines.
Golden, Colorado-based PharmaJet engineers precision delivery systems that overcome the challenges of nucleic acid vaccine delivery. Its Tropis system now offers the delivery of the world’s first plasmid DNA COVID-19 vaccine from Zydus Lifesciences. Exclusively delivered with Tropis, the vaccine demonstrated increased immune response translating into clinical effectiveness, PharmaJet says.
Additionally, Tropis delivers Gennova Biopharmaceutical’s mRNA-based Omicron-specific COVID-19 booster vaccine. The self-amplifying therapeutic enables a low dose of a room temperature, stable mRNA vaccine.
PharmaJet said Tropis already delivered millions of injections in multiple worldwide immunization campaigns. Data repeatedly demonstrated improved immunogenicity for nucleic acid vaccines and therapeutics compared to needle and syringe and electroporation delivery. The company reported efficacy for the Zydus vaccine, plus non-inferior immune response to COVIshield for the Gennova vaccine.
“This marks an important milestone for PharmaJet in that we now have two commercially available nucleic acid-based vaccines in India being exclusively delivered with the Tropis precision delivery system,” said Chris Cappello, PharmaJet president and CEO. “We are well-prepared to rapidly support the demand and look forward to advancing our partnerships and are committed to supporting the advancement of mRNA and DNA vaccines targeting a variety of infectious disease applications for global public health benefit.”